The Medical Oncology Centre of Rosebank
Welcome,         Profile    Billing    Logout  
 8 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rapoport, Bernardo L
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32
Davis, Ian
P3BEP, NCT02582697 / 2015-003060-37 / ACTRN12613000496718: Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Recruiting
3
500
US, RoW
Bleomycin (active name: Bleomycin Sulfate), Blenamax (Aspen), DBL Bleomycin Sulphate (Willow Pharmaceuticals Pty Limited), Bleo Powder for injection (Hospira), Etoposide, DBL Etoposide Injection (Hospira), Etopophos (Bristol-Myers Squibb), Etoposide (Pfizer), Etoposide Ebewe (Sandoz), Cisplatin, Cisplatin Ebewe (Sandoz), Cisplatin injection (Pfizer), DBL Cisplatin Injection (Hospira), Pegylated G-CSF (Pegfilgrastim), Neulasta Syringe with Automatic Needle Guard (Amgen), Filgrastim, Neupogen (Amgen), Nivestim (Hospira), Tevagrastim (Teva Pharma Australia Pty Ltd), Zarzio (Sandoz)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cambridge University Hospitals NHS Foundation Trust, Cancer Trials Ireland, Children's Oncology Group, Dana-Farber Cancer Institute, University of Southern California
Intermediate and poor-risk metastatic germ cell tumours (GCTs)
02/22
07/23
ENZAMET, NCT02446405 / 2014-003190-42 / ACTRN12614000110684: Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

Active, not recruiting
3
1125
Europe, Canada, US, RoW
Enzalutamide, NSAA, LHRHA or Surgical Castration
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Trials Ireland, Canadian Cancer Trials Group, Astellas Pharma Inc
Prostatic Neoplasms
12/26
06/27
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
UNICAB, NCT03685448: ANZUP - Non-clear Cell Post Immunotherapy CABozantinib

Recruiting
2
48
RoW
Cabozantinib, Cabometyx
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2, Chromophobe Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Xp11.2 Translocation-Related Renal Cell Carcinoma
10/22
04/24
KEYPAD, NCT03280667: Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma

Active, not recruiting
2
59
RoW
Pembrolizumab plus denosumab, Keytruda and Xgeva
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Merck Sharp & Dohme LLC, Amgen
Renal Cell Carcinoma, Clear Cell, Metastatic Kidney Cancer
06/23
06/23
CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Active, not recruiting
1/2
21
US
Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
12/24
12/25
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32
Park, Yeon Hee
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Young-PALETTA, NCT04819243: PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

Recruiting
2
178
RoW
Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab, Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib,
Samsung Medical Center
Premenopausal HR+/HER2- Metastatic Breast Cancer
12/25
12/27
KCSG-BR18-13, NCT03698383: Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

Recruiting
2
15
RoW
Trastuzumab biosimilars(Herzuma), Gedatolisib, Herzuma plus Gedatolisib
Korean Cancer Study Group
HER2-positive Breast Cancer, Metastatic Breast Cancer
10/21
12/21
HIPEx, NCT04247633: High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy

Recruiting
2
578
RoW
Palbociclib, Ibrance
Samsung Medical Center, Korean Cancer Study Group
Breast Cancer
02/23
02/25
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Terminated
2
139
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
11/24
11/24
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
NCT03131089: Young Breast Cancer Cohort Study

Recruiting
N/A
2000
RoW
Samsung Medical Center
Breast Cancer
02/18
04/23
NCT03401359: The Resistance and Immune Response to Palbociclib in Breast Cancer

Recruiting
N/A
100
RoW
tissue biopsy, blood sample
Samsung Medical Center
Breast Cancer Stage IV
10/20
10/22
NCT04429633: Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Recruiting
N/A
136
RoW
Candesartan
Samsung Medical Center
Cardiotoxicity, Breast Cancer, Prevention, Adjuvant, Trastuzumab
07/22
07/23
WGS SIT, NCT06334471: Whole Genome Sequencing in Breast Cancer

Recruiting
N/A
1200
RoW
no intervention needed
Inocras Korea Inc.
Breast Cancer
08/25
12/30
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
NCT05910710: Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Recruiting
N/A
50
RoW
Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
Samsung Medical Center
Triple Negative Breast Cancer, Neoadjuvant Chemotherapy, Pembrolizumab, Tumor Microenvironment
12/25
12/25
Eeden, Ronwyn Van
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
Rapoport, Bernado
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 

Download Options